Esperion surges on Phase IIb cholesterol-lowering data
This article was originally published in Scrip
Executive Summary
Esperion Therapeutics jumped 29.2% to a new all-time high of $99.60 per share on 17 March after the company reported that ETC-1002 lowered LDL cholesterol by up to 24% in combination with a low- to moderate-dose statin in a placebo-controlled Phase IIb clinical trial.